Estrogen, Blood Pressure, and the Brain Signal Nobody's Tracking
Quick Summary
A new study maps exactly how estrogen regulates a brain region that controls blood pressure — and what happens when that estrogen disappears after menopause. Nykki also covers two case reports that surface important gaps in how we screen and manage hormone-sensitive conditions in women, and why both are worth knowing about even though they're rare.
Estrogen, Blood Pressure, and the Brain Signal Nobody's Tracking
Key Takeaways
- ✦Estrogen appears to suppress a specific oxidative stress signal in the brainstem that, when unchecked, drives blood pressure up — a brain-based mechanism that's largely missing from the standard "lifestyle and salt" conversation about postmenopausal hypertension.
- ✦The NADPH oxidase pathway in the rostral ventrolateral medulla is not on most clinicians' radar for midlife women, but this research suggests it should factor into how we understand why blood pressure rises after menopause even in women who haven't changed their diet or weight.
- ✦HPV-associated cancers can appear in pelvic tissue with no clear origin point — which is a reason cervical screening history matters, and why "unknown primary" doesn't mean "unexplained."
- ✦Brain tumors during pregnancy are managed very differently than in non-pregnant patients, and the case reported here is a reminder that hormone-sensitive tissue throughout the body responds to pregnancy hormones in ways that are still being mapped.
- ✦All three of today's items point to the same gap: women's cardiovascular and neurological health is under-researched relative to its complexity, and the standard clinical frameworks often miss the hormone connection entirely.
Sources & References
Episode Script
Thanks Toni. We've got some dense science today, so I'm going to try to make it actually useful.
Three items on the table. Two of them are case reports — single-patient stories from clinical journals, which I'll explain why I'm including — and one is a mechanistic study that I think deserves a lot more attention than it's getting. We're going to spend the most time on that one, because it touches something that affects a huge number of women in perimenopause and after, and the explanation has been missing from the conversation.
Let's start there.
A paper published August 14th by Jin and colleagues looks at why blood pressure tends to climb after menopause — and they're not looking at the usual suspects. Not sodium. Not weight. Not arterial stiffness, though that's real and relevant. They're looking at the brain.
Specifically, there's a region in the brainstem called the rostral ventrolateral medulla. That's a mouthful, so just think of it as a blood pressure control center. It's the part of your brain that regulates how much pressure your nervous system tells your heart and blood vessels to maintain. And it turns out estrogen has been quietly keeping a particular stress signal in that region in check.
The stress signal is produced by something called NADPH oxidase — an enzyme that generates a reactive molecule your body uses in small amounts for normal function, but in larger amounts causes damage. When estrogen is present, it appears to suppress that enzyme's activity in this brain region. When estrogen drops — as it does during and after menopause — that suppression lifts, the enzyme gets more active, the oxidative stress in that brainstem region goes up, and blood pressure follows.
This is what researchers call neurogenic hypertension. Neuro meaning it originates in the nervous system, not in the heart or the vessels themselves. The signal is coming from your brain.
Now, this is animal research. I want to be clear about that. The mechanisms here have been worked out in rodent models, which means we can't directly translate every number to human physiology. But mechanistic animal studies like this are exactly how we build toward understanding what's happening in humans — they map the pathway, they give us something to test, and they give clinicians a framework that the "eat less salt, exercise more" conversation just doesn't provide.
And my actual position on this: I think the neurogenic piece of postmenopausal hypertension is under-recognized in clinical practice. The standard conversation a woman gets when her blood pressure creeps up in her late 40s or 50s tends to be about lifestyle. Which is not wrong — lifestyle absolutely matters. But if the signal is originating in a brain region that estrogen was regulating, and that estrogen is now gone, the lifestyle conversation is incomplete. It doesn't explain the mechanism, and it doesn't point toward the right solutions.
The kind of evidence your doctor would look at on a tool like OpenEvidence still treats postmenopausal hypertension largely as a vascular and metabolic issue. This research suggests the neural component deserves a seat at the table. That matters for how we think about treatment — and also for why some women find that blood pressure management gets harder after menopause even when nothing else about their habits has changed.
The second item today is a case report, and I want to explain what that means before I get into it. A case report is the documentation of one patient's unusual or instructive experience. It's not a study. It doesn't prove anything on its own. What it does is flag something worth paying attention to — either because it's rare and doctors need to know it exists, or because it reveals a gap in how we diagnose or treat.
This one, published by Sun and colleagues in 2026, documents a patient who developed a pelvic squamous cell carcinoma — a type of cancer — that was linked to HPV, but had no identifiable primary source. Meaning they couldn't find where it started. It appeared to originate in pelvic tissue, but there was no clear tumor at a standard origin site like the cervix.
HPV-associated cancers usually have a traceable starting point. Cervical cancer, some vulvar cancers, some anal and oropharyngeal cancers — the connection to HPV is well established, and the primary site is usually identifiable. This case was unusual because it wasn't. The cancer was there, HPV was implicated, and the primary origin was unknown.
Why does this matter for a menopause podcast? A few reasons. HPV screening history is relevant to any woman in midlife. Cervical cancer incidence actually peaks in the 40s and 50s for some populations — it's not just a younger woman's concern. And the fact that HPV-associated cancers can present in ways that don't fit the standard screening framework is worth knowing. If you've had gaps in Pap smear or HPV testing, that's worth raising with your doctor, not because this one case is a reason to panic, but because screening gaps are real and common.
The case also illustrates something that comes up repeatedly in women's health: unusual presentations get labeled "unknown origin" and sometimes get deprioritized as a result. One patient's documented journey through that diagnostic gap is useful. It gives clinicians a data point. It gives patients language to push back if they're not getting answers.
The third item is also a case report, published by Vera and colleagues in August 2026. A pregnant woman with a type of brain tumor called a meningioma — specifically a meningoendothelial meningioma, which is the most common subtype — was managed through a high-risk pregnancy and delivery.
Meningiomas are interesting in the context of women's hormonal health because they're significantly more common in women than in men, and they appear to be responsive to progesterone. Some of them have progesterone receptors. During pregnancy, when progesterone is very high, these tumors can grow faster. That's why a pregnant patient with a meningioma is a genuinely complicated clinical situation — you're managing two hormone-sensitive systems at once.
The case report details how the team navigated that. I'm not going to walk through the clinical management step by step because that gets into territory that belongs in a neurology journal, not a podcast. What I find worth highlighting is the broader point it makes about hormone-sensitive tissue throughout the body.
We tend to talk about estrogen and progesterone in terms of the uterus, ovaries, and bones. Sometimes the brain, when we talk about mood and cognition. But there is hormone-sensitive tissue in a lot of places — including the meninges, the membranes that surround the brain and spinal cord. The fact that meningiomas are so much more common in women, and that they appear to respond to progesterone, is a piece of the puzzle that a lot of women in perimenopause don't know about. Not because they're at high risk — most aren't — but because it's a demonstration of how far-reaching these hormonal systems are.
If you've been told you have a meningioma, or if one is being monitored, the hormonal context is worth discussing with your neurologist, especially if you're in perimenopause or considering hormone therapy of any kind. That's not a reason to avoid treatment — it's a reason to have a fuller conversation.
The gap I keep coming back to with both of these case reports is that hormone-sensitive conditions in women are still being mapped. We don't have complete pictures. The clinical frameworks are catching up. And in the meantime, women are navigating diagnoses without always having the full context for why their hormonal history might be relevant.
That's the brainstem, the pelvic tissue, and the meninges — three very different anatomical locations, all connected to hormonal systems that are in flux during and after menopause, and all under-represented in the standard clinical conversation about midlife health.
Sources curated automatically by the Hot Flasher pipeline.
Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.